Traitements3programmes
Essais2liés
Publications0liées
SourceDBlocale

Traitements

3
MoléculeIndication / populationPhaseObjectifPaysRésultat
ITI-1284This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled, flexible-dose study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo in the treatment of psychosis in patients with AD. Alzheimer Phase 2 À vérifier United States, Bulgaria, Croatia, Czechia, Romania, Serbia, Slovakia, Spain À vérifier
ITI-1284This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled, flexible-dose study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo in the treatment of psychosis in patients with AD. Alzheimer Phase 2 À vérifier United States, Bulgaria, Croatia, Czechia, Italy, Poland, Romania, Serbia, Slovakia, Spain À vérifier
ITI-1284This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled, flexible-dose study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo in the treatment of psychosis in patients with AD. Alzheimer Phase 2 À vérifier United States, Bulgaria, Croatia, Czechia, Romania, Serbia, Slovakia, Spain À vérifier

Essais cliniques

2
MoléculeIndication / populationPhaseNCTTitreStatut
ITI-1284 Alzheimer Phase 2 NCT06651567 A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia RECRUITING
ITI-1284 Alzheimer Phase 2 NCT06540833 A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease RECRUITING

Publications

0
MoléculeIndication / populationTitreJournalDate
Aucune publication.